Rasagiline | Medicues
Links shared publicly online about this topic.
- 1,760total visits
Rasagiline | Medicues
View full resource at medicues.com
Tags: Parkinson's Disease, Parkinson's Disease Medication, Disease and Condition, Drug
Most Recently Shared on September 10, 2009 at 8:29 am By:
Rasagiline: · Trade Name Azilect · Generic Name RASAGILINE · Drug Class Parkinson’s Disea.. http://bit.ly/guPiS www.medicues.com
MT @ParkinsonDotOrg Joint statement from 6 #Parkinsons orgs about FDA hearing 2 change labeling on Azilect (rasagiline) http://t.co/ZXwNntnF
parkinson.org — “MT @ParkinsonDotOrg Joint statement from 6 #Parkinsons orgs about FDA hearing 2 change labeling on Azilect (rasagiline) http://t.co/ZXwNntnF” View full resource at parkinson.org
Most Recently Shared on October 17, 2011 at 8:15 pm By:
Parkinson's SanDiego Health Organization
MT @ParkinsonDotOrg Joint statement from 6 #Parkinsons orgs about FDA hearing 2 change labeling on Azilect (rasagiline) http://t.co/ZXwNntnF
Medical News: Parkinson's Drug Doesn't Slow Disease Progress, FDA Staff Says - in Neurology, Parkinson's Disease from MedPage Today
medpagetoday.com — “WASHINGTON -- Azilect (rasagiline), which is already approved to treat symptoms of Parkinson's disease, does not appear effective at slowing progression of the neurodegenerative disease, according to” View full resource at medpagetoday.com
Most Recently Shared on October 14, 2011 at 9:59 pm By:
Parkinson's Drug Doesn't Slow Disease Progress, FDA Staff Says - in Neurology, - http://t.co/kGJft1rq from @medpagetoday
Neurology Article | Parkinson Disease
mdlinx.com — “Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinsons disease” View full resource at mdlinx.com
Most Recently Shared on September 19, 2011 at 2:52 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinsons disease: European Jo... http://t.co/z9X7GkKp #neuro
Family Medicine Article | Parkinson Disease
mdlinx.com — “Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinsons disease” View full resource at mdlinx.com
Most Recently Shared on August 9, 2011 at 4:31 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Park... http://bit.ly/o8UGr6 #FamPractice
Neurology Article | Parkinson Disease
mdlinx.com — “Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinsons disease” View full resource at mdlinx.com
Most Recently Shared on August 8, 2011 at 8:49 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinsons... http://bit.ly/opEfNc #neuro
5and5 Rasagiline (Azilect): 5 Risks/Side-Effects vs. 5 Benefits Analysis | Dopadoc Parkinson's International
dopadoc.com — “5and5 Rasagiline (Azilect): 5 Risks/Side-Effects vs. 5 Benefits Analysis | Dopadoc Parkinson's International” View full resource at dopadoc.com
Most Recently Shared on May 18, 2011 at 2:44 am By:
Marshall Davidson MD Anesthesiologist, Physician, and Doctor
Teva's #Azilect patents begin expiring next year 2012 http://bit.ly/iEGF3J maybe generic #rasagiline will be AS or LESS expensive than GOLD!
ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
sciencedirect.com — “ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes” View full resource at sciencedirect.com
Most Recently Shared on April 16, 2011 at 9:01 am By:
Analysis of the results of the ADAGIO study will inform us of future clinical trial design. http://t.co/NEyDoKq
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study - Hanagasi - 2011 - Movement Disorders - Wiley Online Library
onlinelibrary.wiley.com — “The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study - Hanagasi - 2011 - Movement Disorders - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on April 15, 2011 at 3:00 pm By:
Movement Disorders Health Organization and Neurology
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, ... http://bit.ly/eqBF3M
Theme: Prevention of Progression in PD | .............Dopadoc Parkinson's International
dopadoc.com — “We're keeping that as the single theme all week to adequately cover the following items/possibilities: Azilect(rasagiline) isradipine ibuprofen dopamine agonists coenzyme Q10 caffeine nicotine vitamin E vitamin B6 exercise games (eg. Nintendo) avoiding amphetamines Since disability is along the road of disease progression we'll also address that a bit this week.” View full resource at dopadoc.com
Most Recently Shared on March 13, 2011 at 7:36 pm By:
Marshall Davidson MD Anesthesiologist, Physician, and Doctor
http://www.dopadoc.com/?p=2035 Theme Page: Prevention of Progression of PD
Slowing Progression of Symptoms in Parkinson's: What works? | .............Dopadoc Parkinson's International
dopadoc.com — “Slowing Progression in Parkinson's, Final Word March 2011 (Azilect (rasagiline), isradipine, ibuprofen, coenzyme q10, vitamin E, L-dopa, DA agonists, nicotine, caffeine and exercise)” View full resource at dopadoc.com
Most Recently Shared on March 11, 2011 at 11:32 pm By:
ingentaconnect Cost Effectiveness of Rasagiline and Pramipexole as Treatment Str...
ingentaconnect.com — “ingentaconnect Cost Effectiveness of Rasagiline and Pramipexole as Treatment Str...” View full resource at ingentaconnect.com
Most Recently Shared on February 2, 2011 at 11:35 pm By:
Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsons Disease in the UK S... http://bit.ly/hf8mxe
[Rasagiline: effectiveness and protection in Parki... [Rev Neurol. 2010] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on October 30, 2010 at 9:58 pm By:
[Rasagiline: effectiveness and protection in Parkinson's disease.]: CONCLUSIONS. Comparatively, rasagiline has pro... http://bit.ly/9C0eS6
Monoamine Oxidase Type B Inhibitors in the Treatment of Early Parkinson's Disease | Neurology
touchneurology.com — “Parkinson's disease, monoamine oxidase type B (MAO-B) inhibitors, rasagiline, selegiline, Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, Rasagiline Mesylate (TVP-1012) in Early Monotherapy for PD Outpatients (TEMPO)” View full resource at touchneurology.com
Most Recently Shared on October 24, 2010 at 12:15 pm By:
touchNEURO Health Site and Neurology
Monoamine Oxidase Type B treatment - http://ow.ly/2V5ab
Teva and Watson Wrangle over Possible Generic Version of Azilect | PD Online Research
pdonlineresearch.org — “Teva and Watson Wrangle over Possible Generic Version of Azilect | PD Online Research” View full resource at pdonlineresearch.org
Most Recently Shared on October 8, 2010 at 6:11 pm By:
PD Online Research Health Organization
Teva and Watson wrangle over Watson's plan to produce generic Azilect (rasagiline), a Parkinson's treatment. http://bit.ly/bxWdC0
Watson seeks FDA approval to market rasagiline mesylate tablets
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.” View full resource at news-medical.net
Most Recently Shared on October 6, 2010 at 6:49 am By:
Watson seeks FDA approval to market rasagiline mesylate tablets: Watson Pharmaceuticals, Inc. today confirmed that... http://bit.ly/c4479C
Advertisement
